TY - JOUR
T1 - Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers
AU - Pluta, Ryszard M.
AU - Oldfield, Edward H.
AU - Bakhtian, Kamran D.
AU - Fathi, Ali Reza
AU - Smith, René K.
AU - DeVroom, Hetty L.
AU - Nahavandi, Masoud
AU - Woo, Sukyung
AU - Figg, William D.
AU - Lonser, Russell R.
PY - 2011
Y1 - 2011
N2 - Background: Infusion of sodium nitrite could provide sustained therapeutic concentrations of nitric oxide (NO) for the treatment of a variety of vascular disorders. The study was developed to determine the safety and feasibility of prolonged sodium nitrite infusion. Methodology: Healthy volunteers, aged 21 to 60 years old, were candidates for the study performed at the National Institutes of Health (NIH; protocol 05-N-0075) between July 2007 and August 2008. All subjects provided written consent to participate. Twelve subjects (5 males, 7 females; mean age, 38.8±9.2 years (range, 21-56 years)) were intravenously infused with increasing doses of sodium nitrite for 48 hours (starting dose at 4.2 μg/kg/hr; maximal dose of 533.8 μg/kg/hr). Clinical, physiologic and laboratory data before, during and after infusion were analyzed. Findings: The maximal tolerated dose for intravenous infusion of sodium nitrite was 267 μg/kg/hr. Dose limiting toxicity occurred at 446 μg/kg/hr. Toxicity included a transient asymptomatic decrease of mean arterial blood pressure (more than 15 mmHg) and/or an asymptomatic increase of methemoglobin level above 5%. Nitrite, nitrate, S-nitrosothiols concentrations in plasma and whole blood increased in all subjects and returned to preinfusion baseline values within 12 hours after cessation of the infusion. The mean half-life of nitrite estimated at maximal tolerated dose was 45.3 minutes for plasma and 51.4 minutes for whole blood. Conclusion: Sodium nitrite can be safely infused intravenously at defined concentrations for prolonged intervals. These results should be valuable for developing studies to investigate new NO treatment paradigms for a variety of clinical disorders, including cerebral vasospasm after subarachnoid hemorrhage, and ischemia of the heart, liver, kidney and brain, as well as organ transplants, blood-brain barrier modulation and pulmonary hypertension.
AB - Background: Infusion of sodium nitrite could provide sustained therapeutic concentrations of nitric oxide (NO) for the treatment of a variety of vascular disorders. The study was developed to determine the safety and feasibility of prolonged sodium nitrite infusion. Methodology: Healthy volunteers, aged 21 to 60 years old, were candidates for the study performed at the National Institutes of Health (NIH; protocol 05-N-0075) between July 2007 and August 2008. All subjects provided written consent to participate. Twelve subjects (5 males, 7 females; mean age, 38.8±9.2 years (range, 21-56 years)) were intravenously infused with increasing doses of sodium nitrite for 48 hours (starting dose at 4.2 μg/kg/hr; maximal dose of 533.8 μg/kg/hr). Clinical, physiologic and laboratory data before, during and after infusion were analyzed. Findings: The maximal tolerated dose for intravenous infusion of sodium nitrite was 267 μg/kg/hr. Dose limiting toxicity occurred at 446 μg/kg/hr. Toxicity included a transient asymptomatic decrease of mean arterial blood pressure (more than 15 mmHg) and/or an asymptomatic increase of methemoglobin level above 5%. Nitrite, nitrate, S-nitrosothiols concentrations in plasma and whole blood increased in all subjects and returned to preinfusion baseline values within 12 hours after cessation of the infusion. The mean half-life of nitrite estimated at maximal tolerated dose was 45.3 minutes for plasma and 51.4 minutes for whole blood. Conclusion: Sodium nitrite can be safely infused intravenously at defined concentrations for prolonged intervals. These results should be valuable for developing studies to investigate new NO treatment paradigms for a variety of clinical disorders, including cerebral vasospasm after subarachnoid hemorrhage, and ischemia of the heart, liver, kidney and brain, as well as organ transplants, blood-brain barrier modulation and pulmonary hypertension.
UR - http://www.scopus.com/inward/record.url?scp=79251547703&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0014504
DO - 10.1371/journal.pone.0014504
M3 - Article
C2 - 21249218
AN - SCOPUS:79251547703
SN - 1932-6203
VL - 6
JO - PLoS ONE
JF - PLoS ONE
IS - 1
M1 - e14504
ER -